On June 15, 2023 the U.S. Food and Drug Administration (FDA) announced it has approved glofitamab-gxbm (Columvi, Genentech, Inc.) for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.

“People with relapsed or refractory DLBCL who have already received treatment are in need of additional treatment options,” said Meghan Gutierrez, Chief Executive Officer of the Lymphoma Research Foundation. “The approval of glofitamab-gxbm helps change the way these patients are treated and provides an innovative new option to those impacted by this subtype of lymphoma.”

For more information on the FDA approval of glofitamab-gxbm (Columvi, Genentech, Inc.), visit the FDA’s website.  To learn more about treatment options for DLBCL, visit the DLBCL learning center.